Intellia's (NTLA) NTLA-2002 and NTLA-2001 Data Continue to Validate Approach - Brookline Capital Bullish on Stock
Tweet Send to a Friend
Brookline Capital Markets analyst Leah RUsh Cann reiterated a Buy rating and $91.00 price target on Intellia Therapeutics (NASDAQ: NTLA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
